Maternal factors of pre-eclampsia development




preeclampsia, obesity, height, first pregnancy, chronic kidney disease


Study objective: to determine the most important maternal factors for the pre-eclampsia (PE) prediction, which are used in screening of women when registered for pregnancy.
Materials and methods. A prospective cohort study included 91 pregnant women in their first trimester; study period 2018–2020. The main group included 56 (61.54%) women with a number of maternal factors for PE development, and 35 (38.46%) were healthy females in the control group. Subgroups of women formed for females with and without PE – 28.57% and 71.43%, respectively.
Results. Statistically significant values in the study of maternal factors were observed between subgroups of patients with and without PE for body mass index (BMI) prior to pregnancy (26.83 ± 1.29 and 26.03 ± 1.05) and height of pregnant women (163.35 ± 1.26 cm and 167.23 ± 1.02 cm), p <0.05. Among the risk factors that led to PE, statistically significant results were observed when combining the first pregnancy with a history of kidney disease (p = 0.033). Recurrent PE was observed when combined with PE history in mother (p = 0.011). Impact of chronic hypertension on the PE development was noted when the disease history was over 5 years. The combination of interval between pregnancies of 10 years and more and age >35 years was associated with PE (p = 0.008).
During IVF PE developed in combination with such factors as BMI 30 kg/m2 and the interval between pregnancies over 10 years, 1.1% females had no other factors. History of renal disease and the age >35 years had an impact on the PE development in patients with anti-phospholipid syndrome. Analysis of the odds ratio of the isolated maternal factor showed the following indicators: PE during previous pregnancy – 6, multiple pregnancy – 2.56, anti-phospholipid syndrome – 2.56, first pregnancy – 1.83, in vitro fertilization – 1.72, obesity >30 kg/m2 – 1.65, PE in the mother – 1.57, age >35 years – 1.08, history of renal disease – 1, interval between pregnancies >10 years – 0.77 and chronic hypertension – 0.18.
Conclusion. Thorough monitoring of maternal risk factors for PE should focus on PE during previous pregnancy. The second position is occupied by multiple pregnancy and anti-phospholipid syndrome. PE risk is increased for a combination of factors, especially with chronic renal disease and/or elevated BMI.

Author Biographies

L.I. Berlinska, Odesa National Medical University

Assistant, Department of Obstetrics and Gynecology

V.G. Marichereda, Odesa National Medical University

MD, professor, Department of Obstetrics and Gynecology

M.Y. Holubenko, Odesa National Medical University; Maternity Hospital No. 2

MD, professor, Department of Obstetrics and Gynecology;

Chief physician

O.M. Pavlovska, Odesa National Medical University

PhD, assistant, associate professor, Department of Obstetrics and Gynecology


  1. Poon, L.C., Shennan, A., Hyett, A.J., et al. “The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention.” Int J Gynecol Obstet 145.1 (2019): 1–33.
  2. Bergen, N.E., Schalekamp-Timmermans, S., Roos-Hesselink, J., et al. “Hypertensive disorders of pregnancy and subsequent maternal cardiovascular health.” European Journal of Epidemiology 33 (2018): 763–71. DOI: 10.1007/s10654-018-0400-1
  3. Lopes, V.A., Spaan, J.J., Cornelis, T. “Prevalence of chronic kidney disease after preeclampsia.” Journal of Nephrology 30 (2017): 403–9.
  4. Brown, M.A., Magee, L.A., Kenny, L.C., et al. “The hypertensive disorders of pregnancy: ISSHP classification, diagnosis and management recommendations for international practice.” Pregnancy Hypertens 13 (2018): 291–310.
  5. Walker, K.F., Thornton, J.G. “Advanced Maternal Age.” Obstetrics, Gynaecology and Reproductive Medicine 26 (2016): 354–7. DOI: 10.1016/j.ogrm.2016.09.005
  6. Mame Diarra Ndiaye, et al. “The Impact of Extreme Maternal Ages on Hypertensive Disorders of Pregnancy: A Retrospective Cohort Study in Dakar, Senegal.” Open Journal of Obstetrics and Gynecology 10 (2020): 213–20.
  7. Čerkez Habek, J., et al. “Pregestational obesity – risk factor for preeclampsia.” Med Jad 49.1 (2019): 45–9.
  8. Poorolajal, J., Jenabi, E. “The association between body mass index and preeclampsia: a meta-analysis.” The Journal of Maternal-Fetal & Neonatal Medicine 29.22 (2016): 3670–6.
  9. Wajahat Hussain, Muhammad Arif Khan, Muhammad Imran. “Obesity: A Risk Factor of preeclampsia.” Int J Front Sci 3.2 (2019): 104–7.
  10. Motedayen, M., Rafiei, M., Rezaei Tavirani, M., et al. “The relationship between body mass index and preeclampsia: A systematic review and meta-analysis.” Int J Reprod BioMed 17 (2019): 463–72. DOI: 10.18502/ijrm.v17i7.4857
  11. Lee, Y., Magnus, P. “Maternal and Paternal Height and the Risk of preeclampsia.” Hypertension 71.4 (2018): 666–70. DOI: 10.1161/HYPERTENSIONAHA.117.10477
  12. Lao, T.T., Hui, A.S.Y., Sahota, D.S., Leung, T.Y. “Maternal height and risk of hypertensive disorders in pregnancy.” The Journal of Maternal-Fetal & Neonatal Medicine 32.9 (2019): 1420–5. DOI: 10.1080/14767058.2017.1410786
  13. Bernardes, T.P., Mol, B.W., Ravelli, A.C.J., et al. “Recurrence risk of preeclampsia in a linked population-based cohort: Effects of first pregnancy maximum diastolic blood pressure and gestational age.” Pregnancy Hypertension 15.32 (2019): 32–6.
  14. Galaviz-Hernandez, C., Sosa-Macias, M., Teran, E., et al. “Paternal Determinants in preeclampsia.” Front. Physiol., 07 January 2019
  15. Mignini, L.E., Carroli, G., Betran, A.P., et al. “Interpregnancy interval and perinatal outcomes across Latin America from 1990 to 2009: a large multi-country study.” BJOG 123 (2016): 730–7.
  16. Hanley, E.G., Hutcheon, A.J., Kinniburgh, A.B., Lee, L. “Interpregnancy Interval and Adverse Pregnancy Outcomes.” Obstetrics & Gynecology 129.3 (2017): 408-15. DOI: 10.1097/AOG.0000000000001891
  17. Laine, K., Murzakanova, G., Sole, K.B., et al. “Prevalence and risk of pre-eclampsia and gestational hypertension in twin pregnancies: a population-based register study.” BMJ 9.7 (2019): e029908. DOI: 10.1136/bmjopen-2019-029908
  18. Bilano, V.L., Ota, E., Ganchimeg, T., et al. “Risk Factors of Pre-Eclampsia/Eclampsia and Its Adverse Outcomes in Low- and Middle-Income Countries: A WHO Secondary Analysis.” PLoS ONE 9 (2014): e91198.
  19. Artyomenko, V.V., Berlinska, L.I. “Relevance of the modern renal biomarkers use for the screening of early development of preeclampsia.” Kidneys 7.2 (2018): 81–6.
  20. Hladunewich, M.A. “Chronic Kidney Disease and Pregnancy.” Seminars in Nephrology 37.4 (2017): 337–46. DOI: 10.1016/j.semnephrol.2017.05.005
  21. Brumby, C., Aherne, N., Koh, G., et al. “Risk factors for superimposed preeclampsia in women with chronic hypertension.” Pregnancy Hypertens 13.1 (2018): S119. DOI: 10.1016/j.preghy.2018.08.352
  22. Elliott, S.E., et al. “Characterization of antibody specificities associated with preeclampsia.” Hypertension 63 (2014): 1086–93.
  23. Alijotas-Reig, J., Esteve-Valverde, E., Ferrer-Oliveras, R., et al. “The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases.” Autoimmunity Reviews 18.4 (2019): 406–14. DOI: 10.1016/j.autrev.2018.12.006
  24. Thomopoulos, C., Salamalekis, G., Kintis, K., et al. “Risk of hypertensive disorders in pregnancy following assisted reproductive technology: overview and meta-analysis.” J Clin Hypertens 19.2 (2017): 173–83. DOI: 10.1111/jch.12945
  25. Jing Gui, Zhonghui Ling, Xiaojing Hou, et al. “In vitro fertilization is associated with the onset and progression of preeclampsia.” Placenta 89 (2020): 50–7. DOI: 10.1016/j.placenta.2019.09.011




How to Cite

Berlinska, L., Marichereda, V., Holubenko, M., & Pavlovska, O. (2021). Maternal factors of pre-eclampsia development. REPRODUCTIVE ENDOCRINOLOGY, (58), 102–106.



Pregnancy and childbirth